NASDAQ:IBB - Nasdaq - US4642875565 - ETF - Currency: USD
Experts raise alarms about Health Secretary Robert F. Kennedy Jr's decision to layoff tens of thousands of federal workers, disrupting critical health data collection and research efforts.
Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma.
The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss.
Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH.
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.